ROSEMARY MELESKO: Open Payments
NPI 1609120435 · WHITTIER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,483 in 24 payments from 17 companies in 2025. Trend: 2023 $2,660 · 2024 $1,850 · 2025 $2,483
Food & beverage: $2,483
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 3 | $333 |
| ABIOMED | 2 | $263 |
| ABBVIE INC. | 2 | $250 |
| Axsome Therapeutics, Inc. | 2 | $241 |
| Biogen, Inc. | 2 | $208 |
| AtriCure, Inc. | 2 | $207 |
| Gilead Sciences, Inc. | 1 | $137 |
| Teva Pharmaceuticals USA, Inc. | 1 | $130 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Ultragenyx Pharmaceutical Inc. | 1 | $122 |
Products named: VRAYLAR, Auvelity, SYNERGY ABLATION SYSTEM, Yeztugo, AUSTEDO XR, FANAPT, Dojolvi, KRYSTEXXA.
Industry payments across CA — which companies pay providers there.
